EUVIMEDOpdag EUVIMED
Open access · CC BY-NC-ND 4.0

High Levels of C5a Are Associated With Reduced Macular Sensitivity in Patients With Myeloproliferative Neoplasms

Kathrine Gotfredsen, Andreas Abou-Taha, Charlotte Liisborg, Marie Krogh Nielsen, Morten Kranker Larsen, Vibe Skov, Lasse Kjær, Hans Karl Hasselbalch, Torben Lykke Sørensen

Investigative Ophthalmology & Visual Science · 2025

DOI: 10.1167/iovs.66.2.41 ↗

At a glance

Journal article in Investigative Ophthalmology & Visual Science, 2025. Written by Kathrine Gotfredsen and 8 co-authors. Institution: Department of Ophthalmology, Zealand University Hospital, Roskilde, Denmark. Major MEDLINE topics: Complement C5a, Myeloproliferative Disorders, Macula Lutea, Macular Degeneration. Cited 2 times so far (Crossref); 52 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Purpose

Previous findings indicate that patients with myeloproliferative neoplasms (MPN) exhibit elevated levels of inflammatory biomarkers and have a high prevalence of AMD. In this study, we aim to determine whether drusen and systemic inflammation in patients with MPN affect macular sensitivity in the same manner as in patients with AMD.

Methods

The study was conducted as a prospective cross-sectional study. A total of 139 study eyes of 71 patients were included in this study. We measured macular sensitivity using microperimetry and extracted blood samples to evaluate systemic inflammation markers.

Results

Multilevel linear mixed-effect analysis did not show any difference in macular sensitivity when comparing eyes of MPN patients with AMD to those without drusen (β = -0.254, P = 0.657). However, higher levels of the complement system fragment C5a were significantly correlated with decreased total macular sensitivity (β = -0.561, P = 0.027), irrespective of the presence of drusen.

Conclusions

We found that high levels of the systemic inflammation marker C5a are associated with reduced macular sensitivity, regardless of the presence of visible degenerative changes in the macular area. These findings suggest an early contribution of the complement system to macular sensitivity.

Subjects

MeSH terms (MEDLINE)

Complement C5aMyeloproliferative DisordersMacula LuteaMacular DegenerationVisual FieldsHumansMaleFemaleCross-Sectional StudiesProspective StudiesAgedMiddle AgedBiomarkersVisual Field TestsAged, 80 and overRetinal DrusenTomography, Optical Coherence

Substances

Complement C5aBiomarkers

Authors and institutions

  • Department of Ophthalmology, Zealand University Hospital, Roskilde, Denmark.
  • Department of Ophthalmology, Odense University Hospital, Odense, Denmark.
  • Department of Hematology, Zealand University Hospital, Roskilde, Denmark.

Cite

APA

Gotfredsen, K., Abou-Taha, A., Liisborg, C., Krogh Nielsen, M., Larsen, M. K., Skov, V., Kjær, L., Hasselbalch, H. K., & Sørensen, T. L. (2025). High Levels of C5a Are Associated With Reduced Macular Sensitivity in Patients With Myeloproliferative Neoplasms. Investigative Ophthalmology & Visual Science. https://doi.org/10.1167/iovs.66.2.41

Vancouver

Gotfredsen K, Abou-Taha A, Liisborg C, Krogh Nielsen M, Larsen MK, Skov V, et al. High Levels of C5a Are Associated With Reduced Macular Sensitivity in Patients With Myeloproliferative Neoplasms. Investigative Ophthalmology & Visual Science. 2025. doi:10.1167/iovs.66.2.41

BibTeX
@article{Gotfredsen2025,
  author = {Gotfredsen, Kathrine and Abou-Taha, Andreas and Liisborg, Charlotte and Krogh Nielsen, Marie and Larsen, Morten Kranker and Skov, Vibe and Kjær, Lasse and Hasselbalch, Hans Karl and Sørensen, Torben Lykke},
  title = {High Levels of C5a Are Associated With Reduced Macular Sensitivity in Patients With Myeloproliferative Neoplasms},
  journal = {Investigative Ophthalmology & Visual Science},
  year = {2025},
  doi = {10.1167/iovs.66.2.41}
}
Start for free →